市場調查報告書
商品編碼
1379188
2023-2028 年按產品類型、篩檢、疾病、最終用戶和地區分類的產前和新生兒基因檢測市場報告Prenatal and Newborn Genetic Testing Market Report by Product Type, Screening, Disease, End User, and Region 2023-2028 |
2022年,全球產前和新生兒基因檢測市場規模達到53億美元。展望未來, IMARC Group預計到2028年市場規模將達到112億美元,2022-2028年複合年成長率(CAGR)為13.3%。對先進診斷和篩檢設備的需求不斷成長、世界各地新生兒先天畸形和遺傳異常患病率不斷上升以及醫療行業的蓬勃發展是推動市場的一些關鍵因素。
產前和新生兒基因檢測包括血液檢測、特定類型的超音波檢測和產前遊離 DNA 篩檢,為未出生嬰兒和新生兒的基因組成提供寶貴的見解。它可以識別某些出生缺陷,其中許多是未出生或新生兒的遺傳性疾病。它為準父母、醫療保健專業人員和研究人員提供重要資訊,使他們能夠就嬰兒的健康和福祉做出明智的決定。它有助於改善患者的治療結果並指導醫療干預,同時能夠準確識別懷孕和嬰兒早期的遺傳變異和異常。它還有助於檢測各種先天性疾病,如唐氏症、囊性纖維化、鐮狀細胞疾病和苯酮尿症。由於它有助於分析父母血液中的各種蛋白質水平,以確定嬰兒染色體數量異常的風險,因此全球對產前和新生兒基因檢測的需求正在增加。
目前,全球大眾對先進診斷和篩檢設備的需求不斷成長,是支持市場成長的關鍵因素之一。此外,全世界新生兒先天畸形和基因異常的盛行率增加。這與蓬勃發展的醫療產業一起推動了市場的成長。此外,與傳統方法相比,非侵入性產前篩檢方法具有多種優點,例如準確度高、精確度高、痛苦少、診斷快速等,對市場的需求不斷成長,正在對市場產生積極影響。除此之外,人們對產前和新生兒基因檢測的好處的認知不斷提高,為行業投資者提供了利潤豐厚的成長機會。此外,由於注重健康的個人數量不斷增加,對產前和新生兒基因檢測的需求不斷增加,也促進了市場的成長。除此之外,各國政府機構都致力於改善醫療基礎設施,為國民提供更好的醫療服務。為此,主要參與者正在開發基因眼科測試,以確定患者罹患圓錐角膜和其他角膜營養不良的風險。此外,用於檢測遺傳性疾病風險的母體血漿檢測對無細胞 DNA 的需求不斷成長,這提供了有利的市場前景。
The global prenatal and newborn genetic testing market size reached US$ 5.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.2 Billion by 2028, exhibiting a growth rate (CAGR) of 13.3% during 2022-2028. The growing demand for advanced diagnostic and screening devices, rising prevalence of congenital malformations and genetic abnormalities in newborn babies around the world, and thriving medical industry represent some of the key factors driving the market.
Prenatal and newborn genetic testing comprises blood tests, a specific type of ultrasound, and prenatal cell-free DNA screening that offers invaluable insights into the genetic makeup of unborn babies and newborns. It can identify certain birth defects, many of which are genetic disorders in unborn or newborn babies. It provides critical information to expectant parents, healthcare professionals, and researchers, enabling them to make informed decisions about the health and well-being of infants. It assists in improving patient outcomes and guiding medical interventions while enabling accurate identification of genetic variations and abnormalities during pregnancy and early infancy. It also aids in detecting various congenital conditions, such as Down syndrome, cystic fibrosis, sickle cell disease, and phenylketonuria. As it helps analyze various protein levels in the blood of parents to determine the risk for abnormal chromosome numbers in babies, the demand for prenatal and newborn genetic testing is rising across the globe.
At present, the rising demand for advanced diagnostic and screening devices among the masses across the globe represents one of the key factors supporting the growth of the market. In addition, there is an increase in the prevalence of congenital malformations and genetic abnormalities in newborn babies worldwide. This, along with the thriving medical industry, is propelling the growth of the market. Moreover, the growing demand for non-invasive prenatal screening methods due to their various benefits, such as high accuracy and precision, less pain, and fast diagnosis, as compared to conventional methods, is positively influencing the market. Besides this, the rising awareness among individuals about the benefits of prenatal and newborn genetic testing is offering lucrative growth opportunities to industry investors. Additionally, the escalating demand for prenatal and newborn genetic testing due to the increasing number of health-conscious individuals is contributing to the growth of the market. Apart from this, governing agencies of various countries are focusing on improving healthcare infrastructure to provide enhanced healthcare services to citizens. In line with this, key players are developing genetic eye tests to identify the risk of keratoconus and other corneal dystrophies in patients. Furthermore, the growing demand for cell-free DNA in maternal plasma tests to detect the risk of genetic disorders is offering a favorable market outlook.
IMARC Group provides an analysis of the key trends in each segment of the global prenatal and newborn genetic testing market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product type, screening, disease, and end user.
Consumables
Instruments
The report has provided a detailed breakup and analysis of the prenatal and newborn genetic testing market based on the product type. This includes consumables and instruments. According to the report, consumables represented the largest segment.
Non-invasive Prenatal Testing
Chorionic Villus Sampling
Amniocentesis
Maternal Serum Screening
A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the screening has also been provided in the report. This includes non-invasive prenatal testing, chorionic villus sampling, amniocentesis, and maternal serum screening. According to the report, non-invasive prenatal testing accounted for the largest market share.
Downs Syndrome
Phenylketonuria
Cystic Fibrosis
Sickle Cell Anemia
A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the disease has also been provided in the report. This includes downs syndrome, phenylketonuria, cystic fibrosis, and sickle cell anemia. According to the report, downs syndrome accounted for the largest market share.
Hospital
Maternity and Specialty Clinics
Diagnostic Centers
A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the end user has also been provided in the report. This includes hospital, maternity and specialty clinics, and diagnostic centers. According to the report, hospital accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for prenatal and newborn genetic testing. Some of the factors driving the North America prenatal and newborn genetic testing market included the growing number of pregnant women undergoing genetic screening, rising awareness about various inborn genetic diseases, enhanced healthcare infrastructure, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global prenatal and newborn genetic testing market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, BGI Group, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Ravgen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.